These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19717225)

  • 21. Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article.
    Cham J; Venkateswaran AR; Bhangoo M
    Clin Genitourin Cancer; 2021 Dec; 19(6):563.e1-563.e7. PubMed ID: 34433523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newer therapies in advanced prostate cancer.
    Hegeman RB; Liu G; Wilding G; McNeel DG
    Clin Prostate Cancer; 2004 Dec; 3(3):150-6. PubMed ID: 15636681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
    Schayowitz A; Sabnis G; Goloubeva O; Njar VC; Brodie AM
    Br J Cancer; 2010 Sep; 103(7):1001-7. PubMed ID: 20842117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
    Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
    Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.
    Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
    Cell Death Dis; 2014 Oct; 5(10):e1437. PubMed ID: 25275598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
    Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
    Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
    Cai F; Zhang Y; Li J; Huang S; Gao R
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
    Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
    Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drug development in metastatic prostate cancer.
    Armstrong AJ; George DJ
    Urol Oncol; 2008; 26(4):430-7. PubMed ID: 18593623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.
    Wu J; Yu E
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):607-17. PubMed ID: 24414227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway.
    Hixon ML; Paccagnella L; Millham R; Perez-Olle R; Gualberto A
    Rev Recent Clin Trials; 2010 Sep; 5(3):189-208. PubMed ID: 20533896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
    Ghayad SE; Cohen PA
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.